Technology Is Rapidly Changing Cancer Care
By Sai Balasubramanian, J.D., Forbes
By Sai Balasubramanian, J.D., Forbes
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers Dec 15, 2020, 07:00 ET Read on Cision PR Newswire LP-184 preclinical studies reinforce the drug compound’s potential to effectively cross the blood-brain barrier with significant potency Continued progress in advancing glioblastoma [...]
By Drug Discovery World
By Alex Edwards, Dallas Innovates
By Elaine Quilici, PharmExec.com
By Abby Hardy, BioTuesdays
Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging AgentOct 05, 2020, 07:46 ETRead on Cision PR NewswireDALLAS, Oct. 5, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit [...]
By Reece Armstrong, European Pharmaceutical Manufacturer